These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36157151)

  • 41. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonalcoholic Fatty Liver Disease after Liver Transplant.
    Shetty A; Giron F; Divatia MK; Ahmad MI; Kodali S; Victor D
    J Clin Transl Hepatol; 2021 Jun; 9(3):428-435. PubMed ID: 34221929
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.
    Kim H; Lee K; Lee KW; Yi NJ; Lee HW; Hong G; Choi Y; You T; Suh SW; Jang JJ; Suh KS
    Clin Transplant; 2014 May; 28(5):521-9. PubMed ID: 24579874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonalcoholic Steatohepatitis: A 9-Year Follow Up Cohort Study.
    Mangia A; Piazzolla AV; Squillante MM; Cocomazzi G; Valori VM; Copetti M; Parente P; Attino V; Guido M
    J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233834
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography.
    Tada T; Nishimura T; Yoshida M; Iijima H
    J Med Ultrason (2001); 2020 Oct; 47(4):511-520. PubMed ID: 33089412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two-dimensional shear wave elastography in non-alcoholic fatty liver disease.
    Mendoza YP; Rodrigues SG; Delgado MG; Murgia G; Lange NF; Schropp J; Montani M; Dufour JF; Berzigotti A
    Liver Int; 2022 Jan; 42(1):102-111. PubMed ID: 34821035
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
    Simon TG; Roelstraete B; Hagström H; Loomba R; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1366-1373. PubMed ID: 37604268
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of
    Toda-Oti KS; Stefano JT; Cavaleiro AM; Carrilho FJ; Correa-Gianella ML; Oliveira CPMS
    Metab Syndr Relat Disord; 2022 Mar; 20(2):114-123. PubMed ID: 35020496
    [No Abstract]   [Full Text] [Related]  

  • 49. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
    Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression.
    Hsieh YC; Joo SK; Koo BK; Lin HC; Lee DH; Chang MS; Park JH; So YH; Kim W;
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):388-397.e10. PubMed ID: 35101634
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
    World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
    Pennisi G; Enea M; Falco V; Aithal GP; Palaniyappan N; Yilmaz Y; Boursier J; Cassinotto C; de Lédinghen V; Chan WK; Mahadeva S; Eddowes P; Newsome P; Karlas T; Wiegand J; Wong VW; Schattenberg JM; Labenz C; Kim W; Lee MS; Lupsor-Platon M; Cobbold JFL; Fan JG; Shen F; Staufer K; Trauner M; Stauber R; Nakajima A; Yoneda M; Bugianesi E; Younes R; Gaia S; Zheng MH; Cammà C; Anstee QM; Mózes FE; Pavlides M; Petta S
    Hepatology; 2023 Jul; 78(1):195-211. PubMed ID: 36924031
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study.
    Unger LW; Herac M; Staufer K; Salat A; Silberhumer G; Hofmann M; Trauner M; Rasoul-Rockenschaub S; Soliman T; Reiberger T; Berlakovich GA
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):309-316. PubMed ID: 27922486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography.
    Chen J; Talwalkar JA; Yin M; Glaser KJ; Sanderson SO; Ehman RL
    Radiology; 2011 Jun; 259(3):749-56. PubMed ID: 21460032
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease.
    Nogami A; Yoneda M; Kobayashi T; Kessoku T; Honda Y; Ogawa Y; Suzuki K; Tomeno W; Imajo K; Kirikoshi H; Koide T; Fujikawa H; Saito S; Nakajima A
    Hepatol Res; 2019 Aug; 49(8):872-880. PubMed ID: 30974498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ultrasonographic index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
    Kim JW; Lee CH; Kim BH; Lee YS; Hwang SY; Park BN; Park YS
    Quant Imaging Med Surg; 2022 Mar; 12(3):1815-1829. PubMed ID: 35284276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
    Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.